The findings support Alvotech's bid for interchangeable status for the high-concentration, citrate-free adalimumab biosimilar candidate.
The Icelandic biosimilar developer Alvotech reported positive top-line results of a study of patients who switched between the company’s proposed high-concentration (100 mg/mL), citrate-free adalimumab biosimilar (AVT02) and the originator product (Humira). Top-line clinical results are the audited, comprehensive findings from a trial.
The study could potentially help Alvotech gain US “interchangeable status” for AVT02. An interchangeable designation means pharmacists can substitute a biosimilar for the originator drug at the pharmacy counter without the intervention of a physician. Such a designation could give the product an edge over other adalimumab biosimilars—of which 6 have been approved but none marketed.
For the interchangeable designation, switching studies are required by the FDA to demonstrate that similar patient outcomes can be expected whether patients switch between originator and biosimilar once or more than once. Just 1 biosimilar currently on the US market has an interchangeable designation: Semglee (insulin glargine).
Alvotech reported that no significant differences were observed in clinical efficacy, safety, or immunogenicity between patients in the switching cohort and those who remained on the reference product throughout—the control group. The product would be aimed at the lucrative Humira franchise, which recorded US sales of $16.1 billion in 2020, up 8.4%, partly on the strength of price increases that exceeded the rate of drug inflation.
“Completing this key milestone for Alvotech is an extremely rewarding and a positive step toward providing patients an affordable and accessible alternative to the high-concentration version of Humira,” said Mark Levick, CEO of Alvotech, in a statement.
For the switching study (AVT02-GL-302; NCT04453137), 568 patients were enrolled from roughly 30 clinical centers in the European Union. All patients were initiated on reference product during a lead-in period of 12 weeks, and eligible patients were then randomized to either the switching arm or the control group. The switching cohort received alternate doses of AVT02 and Humira for an additional 16 weeks.
The graphic accompanying this story shows the FDA’s recommended switching study model (Figure).
Boehringer Ingelheim also is seeking US interchangeable status for an adalimumab biosimilar (Cyltezo; BI 695501). This product is a lower-concentration formulation (40 mg/0.8 mL) than AVT02.
In February 2021, Celltrion Healthcare obtained EU marketing authorization for a high-concentration, citrate-free adalimumab biosimilar (Yuflyma). This was the first high-concentration adalimumab biosimilar to reach market.
Alvotech remains engaged in litigation over AVT02 with AbbVie, maker of Humira, which has alleged patent infringement.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.